Diuretic response in acute heart failure: clinical characteristics and prognostic significance

Aim Diminished diuretic response is common in patients with acute heart failure, although a clinically useful definition is lacking. Our aim was to investigate a practical, workable metric for diuretic response, examine associated patient characteristics and relationships with outcome. Methods and r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2014-05, Vol.35 (19), p.1284-1293
Hauptverfasser: Valente, Mattia A. E., Voors, Adriaan A., Damman, Kevin, Van Veldhuisen, Dirk J., Massie, Barrie M., O'Connor, Christopher M., Metra, Marco, Ponikowski, Piotr, Teerlink, John R., Cotter, Gad, Davison, Beth, Cleland, John G.F., Givertz, Michael M., Bloomfield, Daniel M., Fiuzat, Mona, Dittrich, Howard C., Hillege, Hans L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1293
container_issue 19
container_start_page 1284
container_title European heart journal
container_volume 35
creator Valente, Mattia A. E.
Voors, Adriaan A.
Damman, Kevin
Van Veldhuisen, Dirk J.
Massie, Barrie M.
O'Connor, Christopher M.
Metra, Marco
Ponikowski, Piotr
Teerlink, John R.
Cotter, Gad
Davison, Beth
Cleland, John G.F.
Givertz, Michael M.
Bloomfield, Daniel M.
Fiuzat, Mona
Dittrich, Howard C.
Hillege, Hans L.
description Aim Diminished diuretic response is common in patients with acute heart failure, although a clinically useful definition is lacking. Our aim was to investigate a practical, workable metric for diuretic response, examine associated patient characteristics and relationships with outcome. Methods and results We examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial. Day 4 response was used to allow maximum differentiation in responsiveness and tailoring of diuretic doses to clinical response, following sensitivity analyses. We investigated predictors of diuretic response and relationships with outcome. The median diuretic response was −0.38 (−0.80 to −0.13) kg/40 mg furosemide. Poor diuretic response was independently associated with low systolic blood pressure, high blood urea nitrogen, diabetes, and atherosclerotic disease (all P < 0.05). Worse diuretic response independently predicted 180-day mortality (HR: 1.42; 95% CI: 1.11–1.81, P = 0.005), 60-day death or renal or cardiovascular rehospitalization (HR: 1.34; 95% CI: 1.14–1.59, P < 0.001) and 60-day HF rehospitalization (HR: 1.57; 95% CI: 1.24–2.01, P < 0.001) in multivariable models. The proposed metric—weight loss indexed to diuretic dose—better captures a dose–response relationship. Model diagnostics showed diuretic response provided essentially the same or slightly better prognostic information compared with its individual components (weight loss and diuretic dose) in this population, while providing a less biased, more easily interpreted signal. Conclusions Worse diuretic response was associated with more advanced heart failure, renal impairment, diabetes, atherosclerotic disease and in-hospital worsening heart failure, and predicts mortality and heart failure rehospitalization in this post hoc, hypothesis-generating study.
doi_str_mv 10.1093/eurheartj/ehu065
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1537591325</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehu065</oup_id><sourcerecordid>1537591325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-c238e08b0f7ecfa8dfbe6444e1e9b074478981e86748932acc30b0f4f852f1833</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhi0EoqWwMyGPSCjUjj_isKHyKVViAYmJyHHPras0KXY88O9xSWFlOp30vI_uXoTOKbmmpGRTiH4F2vfrKawikeIAjanI86yUXByiMaGlyKRU7yN0EsKaEKIklcdolHOhRC6LMfq4c9FD7wz2ELZdGwC7FmsTe8A_amy1axJyg03jWmd0g81Ke2168C6kYMC6XeCt75Ztt9txcMvW2US2Bk7RkdVNgLP9nKC3h_vX2VM2f3l8nt3OM8M56zOTMwVE1cQWYKxWC1uD5JwDhbImBeeFKhUFJQuuSpZrYxhJMLfpC0sVYxN0OXjTHZ8RQl9tXDDQNLqFLoaKClaIkrJcJJQMqPFdCB5stfVuo_1XRUm1a7X6a7UaWk2Ri7091htY_AV-a0zA1QB0cfu_7hvKBodw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1537591325</pqid></control><display><type>article</type><title>Diuretic response in acute heart failure: clinical characteristics and prognostic significance</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Valente, Mattia A. E. ; Voors, Adriaan A. ; Damman, Kevin ; Van Veldhuisen, Dirk J. ; Massie, Barrie M. ; O'Connor, Christopher M. ; Metra, Marco ; Ponikowski, Piotr ; Teerlink, John R. ; Cotter, Gad ; Davison, Beth ; Cleland, John G.F. ; Givertz, Michael M. ; Bloomfield, Daniel M. ; Fiuzat, Mona ; Dittrich, Howard C. ; Hillege, Hans L.</creator><creatorcontrib>Valente, Mattia A. E. ; Voors, Adriaan A. ; Damman, Kevin ; Van Veldhuisen, Dirk J. ; Massie, Barrie M. ; O'Connor, Christopher M. ; Metra, Marco ; Ponikowski, Piotr ; Teerlink, John R. ; Cotter, Gad ; Davison, Beth ; Cleland, John G.F. ; Givertz, Michael M. ; Bloomfield, Daniel M. ; Fiuzat, Mona ; Dittrich, Howard C. ; Hillege, Hans L.</creatorcontrib><description>Aim Diminished diuretic response is common in patients with acute heart failure, although a clinically useful definition is lacking. Our aim was to investigate a practical, workable metric for diuretic response, examine associated patient characteristics and relationships with outcome. Methods and results We examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial. Day 4 response was used to allow maximum differentiation in responsiveness and tailoring of diuretic doses to clinical response, following sensitivity analyses. We investigated predictors of diuretic response and relationships with outcome. The median diuretic response was −0.38 (−0.80 to −0.13) kg/40 mg furosemide. Poor diuretic response was independently associated with low systolic blood pressure, high blood urea nitrogen, diabetes, and atherosclerotic disease (all P &lt; 0.05). Worse diuretic response independently predicted 180-day mortality (HR: 1.42; 95% CI: 1.11–1.81, P = 0.005), 60-day death or renal or cardiovascular rehospitalization (HR: 1.34; 95% CI: 1.14–1.59, P &lt; 0.001) and 60-day HF rehospitalization (HR: 1.57; 95% CI: 1.24–2.01, P &lt; 0.001) in multivariable models. The proposed metric—weight loss indexed to diuretic dose—better captures a dose–response relationship. Model diagnostics showed diuretic response provided essentially the same or slightly better prognostic information compared with its individual components (weight loss and diuretic dose) in this population, while providing a less biased, more easily interpreted signal. Conclusions Worse diuretic response was associated with more advanced heart failure, renal impairment, diabetes, atherosclerotic disease and in-hospital worsening heart failure, and predicts mortality and heart failure rehospitalization in this post hoc, hypothesis-generating study.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehu065</identifier><identifier>PMID: 24585267</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject><![CDATA[Acute Disease ; Aged ; Analysis of Variance ; Atherosclerosis - complications ; Bumetanide - administration & dosage ; Diabetes Complications - complications ; Diuretics - administration & dosage ; Dose-Response Relationship, Drug ; Drug Resistance ; Dyspnea - prevention & control ; Female ; Furosemide - administration & dosage ; Heart Failure - complications ; Heart Failure - drug therapy ; Humans ; Hypotension - complications ; Male ; Patient Readmission ; Renal Insufficiency - complications ; Sulfonamides - administration & dosage ; Treatment Outcome ; Weight Loss - drug effects ; Xanthines - administration & dosage]]></subject><ispartof>European heart journal, 2014-05, Vol.35 (19), p.1284-1293</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com 2014</rights><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-c238e08b0f7ecfa8dfbe6444e1e9b074478981e86748932acc30b0f4f852f1833</citedby><cites>FETCH-LOGICAL-c443t-c238e08b0f7ecfa8dfbe6444e1e9b074478981e86748932acc30b0f4f852f1833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24585267$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valente, Mattia A. E.</creatorcontrib><creatorcontrib>Voors, Adriaan A.</creatorcontrib><creatorcontrib>Damman, Kevin</creatorcontrib><creatorcontrib>Van Veldhuisen, Dirk J.</creatorcontrib><creatorcontrib>Massie, Barrie M.</creatorcontrib><creatorcontrib>O'Connor, Christopher M.</creatorcontrib><creatorcontrib>Metra, Marco</creatorcontrib><creatorcontrib>Ponikowski, Piotr</creatorcontrib><creatorcontrib>Teerlink, John R.</creatorcontrib><creatorcontrib>Cotter, Gad</creatorcontrib><creatorcontrib>Davison, Beth</creatorcontrib><creatorcontrib>Cleland, John G.F.</creatorcontrib><creatorcontrib>Givertz, Michael M.</creatorcontrib><creatorcontrib>Bloomfield, Daniel M.</creatorcontrib><creatorcontrib>Fiuzat, Mona</creatorcontrib><creatorcontrib>Dittrich, Howard C.</creatorcontrib><creatorcontrib>Hillege, Hans L.</creatorcontrib><title>Diuretic response in acute heart failure: clinical characteristics and prognostic significance</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>Aim Diminished diuretic response is common in patients with acute heart failure, although a clinically useful definition is lacking. Our aim was to investigate a practical, workable metric for diuretic response, examine associated patient characteristics and relationships with outcome. Methods and results We examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial. Day 4 response was used to allow maximum differentiation in responsiveness and tailoring of diuretic doses to clinical response, following sensitivity analyses. We investigated predictors of diuretic response and relationships with outcome. The median diuretic response was −0.38 (−0.80 to −0.13) kg/40 mg furosemide. Poor diuretic response was independently associated with low systolic blood pressure, high blood urea nitrogen, diabetes, and atherosclerotic disease (all P &lt; 0.05). Worse diuretic response independently predicted 180-day mortality (HR: 1.42; 95% CI: 1.11–1.81, P = 0.005), 60-day death or renal or cardiovascular rehospitalization (HR: 1.34; 95% CI: 1.14–1.59, P &lt; 0.001) and 60-day HF rehospitalization (HR: 1.57; 95% CI: 1.24–2.01, P &lt; 0.001) in multivariable models. The proposed metric—weight loss indexed to diuretic dose—better captures a dose–response relationship. Model diagnostics showed diuretic response provided essentially the same or slightly better prognostic information compared with its individual components (weight loss and diuretic dose) in this population, while providing a less biased, more easily interpreted signal. Conclusions Worse diuretic response was associated with more advanced heart failure, renal impairment, diabetes, atherosclerotic disease and in-hospital worsening heart failure, and predicts mortality and heart failure rehospitalization in this post hoc, hypothesis-generating study.</description><subject>Acute Disease</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Atherosclerosis - complications</subject><subject>Bumetanide - administration &amp; dosage</subject><subject>Diabetes Complications - complications</subject><subject>Diuretics - administration &amp; dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Resistance</subject><subject>Dyspnea - prevention &amp; control</subject><subject>Female</subject><subject>Furosemide - administration &amp; dosage</subject><subject>Heart Failure - complications</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Hypotension - complications</subject><subject>Male</subject><subject>Patient Readmission</subject><subject>Renal Insufficiency - complications</subject><subject>Sulfonamides - administration &amp; dosage</subject><subject>Treatment Outcome</subject><subject>Weight Loss - drug effects</subject><subject>Xanthines - administration &amp; dosage</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkD1PwzAQhi0EoqWwMyGPSCjUjj_isKHyKVViAYmJyHHPras0KXY88O9xSWFlOp30vI_uXoTOKbmmpGRTiH4F2vfrKawikeIAjanI86yUXByiMaGlyKRU7yN0EsKaEKIklcdolHOhRC6LMfq4c9FD7wz2ELZdGwC7FmsTe8A_amy1axJyg03jWmd0g81Ke2168C6kYMC6XeCt75Ztt9txcMvW2US2Bk7RkdVNgLP9nKC3h_vX2VM2f3l8nt3OM8M56zOTMwVE1cQWYKxWC1uD5JwDhbImBeeFKhUFJQuuSpZrYxhJMLfpC0sVYxN0OXjTHZ8RQl9tXDDQNLqFLoaKClaIkrJcJJQMqPFdCB5stfVuo_1XRUm1a7X6a7UaWk2Ri7091htY_AV-a0zA1QB0cfu_7hvKBodw</recordid><startdate>20140514</startdate><enddate>20140514</enddate><creator>Valente, Mattia A. E.</creator><creator>Voors, Adriaan A.</creator><creator>Damman, Kevin</creator><creator>Van Veldhuisen, Dirk J.</creator><creator>Massie, Barrie M.</creator><creator>O'Connor, Christopher M.</creator><creator>Metra, Marco</creator><creator>Ponikowski, Piotr</creator><creator>Teerlink, John R.</creator><creator>Cotter, Gad</creator><creator>Davison, Beth</creator><creator>Cleland, John G.F.</creator><creator>Givertz, Michael M.</creator><creator>Bloomfield, Daniel M.</creator><creator>Fiuzat, Mona</creator><creator>Dittrich, Howard C.</creator><creator>Hillege, Hans L.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140514</creationdate><title>Diuretic response in acute heart failure: clinical characteristics and prognostic significance</title><author>Valente, Mattia A. E. ; Voors, Adriaan A. ; Damman, Kevin ; Van Veldhuisen, Dirk J. ; Massie, Barrie M. ; O'Connor, Christopher M. ; Metra, Marco ; Ponikowski, Piotr ; Teerlink, John R. ; Cotter, Gad ; Davison, Beth ; Cleland, John G.F. ; Givertz, Michael M. ; Bloomfield, Daniel M. ; Fiuzat, Mona ; Dittrich, Howard C. ; Hillege, Hans L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-c238e08b0f7ecfa8dfbe6444e1e9b074478981e86748932acc30b0f4f852f1833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acute Disease</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Atherosclerosis - complications</topic><topic>Bumetanide - administration &amp; dosage</topic><topic>Diabetes Complications - complications</topic><topic>Diuretics - administration &amp; dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Resistance</topic><topic>Dyspnea - prevention &amp; control</topic><topic>Female</topic><topic>Furosemide - administration &amp; dosage</topic><topic>Heart Failure - complications</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Hypotension - complications</topic><topic>Male</topic><topic>Patient Readmission</topic><topic>Renal Insufficiency - complications</topic><topic>Sulfonamides - administration &amp; dosage</topic><topic>Treatment Outcome</topic><topic>Weight Loss - drug effects</topic><topic>Xanthines - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valente, Mattia A. E.</creatorcontrib><creatorcontrib>Voors, Adriaan A.</creatorcontrib><creatorcontrib>Damman, Kevin</creatorcontrib><creatorcontrib>Van Veldhuisen, Dirk J.</creatorcontrib><creatorcontrib>Massie, Barrie M.</creatorcontrib><creatorcontrib>O'Connor, Christopher M.</creatorcontrib><creatorcontrib>Metra, Marco</creatorcontrib><creatorcontrib>Ponikowski, Piotr</creatorcontrib><creatorcontrib>Teerlink, John R.</creatorcontrib><creatorcontrib>Cotter, Gad</creatorcontrib><creatorcontrib>Davison, Beth</creatorcontrib><creatorcontrib>Cleland, John G.F.</creatorcontrib><creatorcontrib>Givertz, Michael M.</creatorcontrib><creatorcontrib>Bloomfield, Daniel M.</creatorcontrib><creatorcontrib>Fiuzat, Mona</creatorcontrib><creatorcontrib>Dittrich, Howard C.</creatorcontrib><creatorcontrib>Hillege, Hans L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valente, Mattia A. E.</au><au>Voors, Adriaan A.</au><au>Damman, Kevin</au><au>Van Veldhuisen, Dirk J.</au><au>Massie, Barrie M.</au><au>O'Connor, Christopher M.</au><au>Metra, Marco</au><au>Ponikowski, Piotr</au><au>Teerlink, John R.</au><au>Cotter, Gad</au><au>Davison, Beth</au><au>Cleland, John G.F.</au><au>Givertz, Michael M.</au><au>Bloomfield, Daniel M.</au><au>Fiuzat, Mona</au><au>Dittrich, Howard C.</au><au>Hillege, Hans L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diuretic response in acute heart failure: clinical characteristics and prognostic significance</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2014-05-14</date><risdate>2014</risdate><volume>35</volume><issue>19</issue><spage>1284</spage><epage>1293</epage><pages>1284-1293</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Aim Diminished diuretic response is common in patients with acute heart failure, although a clinically useful definition is lacking. Our aim was to investigate a practical, workable metric for diuretic response, examine associated patient characteristics and relationships with outcome. Methods and results We examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial. Day 4 response was used to allow maximum differentiation in responsiveness and tailoring of diuretic doses to clinical response, following sensitivity analyses. We investigated predictors of diuretic response and relationships with outcome. The median diuretic response was −0.38 (−0.80 to −0.13) kg/40 mg furosemide. Poor diuretic response was independently associated with low systolic blood pressure, high blood urea nitrogen, diabetes, and atherosclerotic disease (all P &lt; 0.05). Worse diuretic response independently predicted 180-day mortality (HR: 1.42; 95% CI: 1.11–1.81, P = 0.005), 60-day death or renal or cardiovascular rehospitalization (HR: 1.34; 95% CI: 1.14–1.59, P &lt; 0.001) and 60-day HF rehospitalization (HR: 1.57; 95% CI: 1.24–2.01, P &lt; 0.001) in multivariable models. The proposed metric—weight loss indexed to diuretic dose—better captures a dose–response relationship. Model diagnostics showed diuretic response provided essentially the same or slightly better prognostic information compared with its individual components (weight loss and diuretic dose) in this population, while providing a less biased, more easily interpreted signal. Conclusions Worse diuretic response was associated with more advanced heart failure, renal impairment, diabetes, atherosclerotic disease and in-hospital worsening heart failure, and predicts mortality and heart failure rehospitalization in this post hoc, hypothesis-generating study.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>24585267</pmid><doi>10.1093/eurheartj/ehu065</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2014-05, Vol.35 (19), p.1284-1293
issn 0195-668X
1522-9645
language eng
recordid cdi_proquest_miscellaneous_1537591325
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Acute Disease
Aged
Analysis of Variance
Atherosclerosis - complications
Bumetanide - administration & dosage
Diabetes Complications - complications
Diuretics - administration & dosage
Dose-Response Relationship, Drug
Drug Resistance
Dyspnea - prevention & control
Female
Furosemide - administration & dosage
Heart Failure - complications
Heart Failure - drug therapy
Humans
Hypotension - complications
Male
Patient Readmission
Renal Insufficiency - complications
Sulfonamides - administration & dosage
Treatment Outcome
Weight Loss - drug effects
Xanthines - administration & dosage
title Diuretic response in acute heart failure: clinical characteristics and prognostic significance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A24%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diuretic%20response%20in%20acute%20heart%20failure:%20clinical%20characteristics%20and%20prognostic%20significance&rft.jtitle=European%20heart%20journal&rft.au=Valente,%20Mattia%20A.%20E.&rft.date=2014-05-14&rft.volume=35&rft.issue=19&rft.spage=1284&rft.epage=1293&rft.pages=1284-1293&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehu065&rft_dat=%3Cproquest_cross%3E1537591325%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1537591325&rft_id=info:pmid/24585267&rft_oup_id=10.1093/eurheartj/ehu065&rfr_iscdi=true